ClinicalTrials.gg
CompletedNCT06394843Updated Nov 13, 2026

Fluid Currents During Hemodialysis

An observational study in Patients Undergoing Hemodialysis, sponsored by Joachim Zdolsek. Completed at 1 site in Sweden. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Joachim Zdolsek · Observational

How we know

Updated Nov 13, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
30
Ages
18 Years to 85 Years
Sex
All
01

Study summary

During dialysis, three objectives are achieved. 1. Blood is cleansed from waste products. 2. Excess water is removed. 3. Electrolytes are regulated. These processes occur simultaneously but vary from patient to patient depending on their specific needs. Some patients still produce urine, but of poor quality. Others have no residual urine production at all and require removal of fluid from both blood and tissues. Hypotension may occur during dialysis, related to intravascular hypovolemia and inadequate fluid reinfusion, which is common during ultrafiltration exceeding 400 ml/h. The amount of fluid removed is influenced by fluid recruitment from tissues. This mainly occurs in two different ways: osmotic recruitment across capillary membranes from the perivascular space or via lymphatic reflow. The proportions are not fully understood. When fluid is recruited from the perivascular space, the influx of albumin and immunoglobulins is unlikely. However, these should accompany lymph to the blood if lymphatic flow is increased. The content of albumin and immunoglobulins differs between lymph and plasma. Thus, the proportions of fluid recruitment from tissues should be calculable using mass balance calculations based on ultrafiltrate, colloid osmotic pressure, hemoglobin, albumin, and immunoglobulin concentrations. The rate and proportions of fluid reinfusion into the bloodstream are not fully understood. Therefore, in this study, the aim is to monitor fluid reinfusion and its proportions of lymph/osmotic recruitment into the bloodstream.

Read the detailed description

In Sweden, approximately 3200 patients undergo hemodialysis annually. In some cases, it is solely about blood purification, but for many patients, removal of excess fluid accumulated since the last dialysis treatment is also necessary. The amount of fluid removal/ultrafiltration prescribed by the physician during dialysis primarily depends on the amount of residual urine the patient produces but also on the patient's fluid intake between dialysis treatments. The most common complication of hemodialysis is hypotension during treatment, occurring in about 10% of treatment sessions according to previous studies. These hypotensive episodes lead to temporary hypoperfusion, and repeated episodes can cause permanent organ damage. The main cause of these hypotensive episodes is the reduction in circulating volume during ultrafiltration, i.e., fluid removal. The excess fluid that the patient accumulates between treatments is mainly located outside the bloodstream. Therefore, in connection with fluid removal during hemodialysis, there is compensatory fluid recruitment to the circulation, increasing the circulating volume and preventing hypotension. How this occurs and from which fluid compartment fluid is recruited is not yet mapped out. To increase understanding of hemodialysis and optimize treatment while minimizing the risk of hypotension, it is interesting to understand how fluid recruitment occurs and from which fluid compartments recruitment occurs. Using fluid kinetic calculations, it has been possible to measure whether fluid is recruited perivascularly or from the lymphatic system during albumin infusion depending on the concentrations of proteins such as IgG and IgM, as their concentrations differ. By measuring the concentrations of these proteins in blood samples over time, it has been possible to calculate from which fluid compartment fluid has been recruited.

Purpose and Objective

The aim is to study:

  • How much fluid is drawn from the interstitial space during dialysis, depending on whether fluid removal is needed or not.
  • The size and rate of fluid reinfusion during ongoing dialysis.
  • The composition of the recruited fluid from the interstitium, i.e., the proportion consisting of lymph/lymph reflow and the proportion recruited across capillary membranes/venulae from the pericapillary space.

Hypotheses The null hypothesis is that no detectable difference in fluid flows or source of fluid recruitment is found, between patients where a large volume is dialyzed and those patients who do not have significant fluid removal during dialysis.

The alternative hypothesis is that a clinical relevant difference in fluid flows from the interstitium and the pathway for fluid recruitment to the bloodstream is detected.

Outcome Measures

Primary outcome variables are:

Recruitment of fluid from the interstitium calculated from fluid removal and hemoglobin changes. Proportion of recruited fluid via lymph or via capillary/venulae walls based on fluid recruitment and changes in plasma albumin and immunoglobulins G and M.

Secondary outcome variables are:

Weight, blood pressure impact, and changes in bioimpedance variables.

Study Design:

Open-label, prospective clinical observational study, where patients are divided into two groups. One group with an intact urine production, and dialysis is performed solely to "cleanse" the blood and second group with little or no urine production, which requires significant fluid removal, in addition to blood purification, .

02

Conditions studied

  • Patients Undergoing Hemodialysis

Keywords

  • Hemodialysis
03

In context

Lead sponsor

Joachim Zdolsek is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing hemodialysis regularly at the dialysis department at Vrinnevisjukhuset in Norrköping are screened if they are expected to meet the inclusion criteria for the study. Those who meet the inclusion criteria and have no exclusion criteria are asked to participate.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing hemodialysis (\<500 ml or >2000 ml ultrafiltration)

Exclusion criteria

Exclusion Criteria:

  • Patients who may be affected by blood sampling, i.e., have low concentration independent of dilution before dialysis (Hb 85 g/L).
  • Patients who drink large amounts of water during regular dialysis (> 2 glasses, approximately 0.5 L).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
30 participants (actual)
Patient registry
No

Groups and cohorts

  • <500 ml Ultrafiltration

    Patients undergoing hemodialysis with less than 500 ml ultrafiltration

    Other: Ultrafiltration

  • >2000 ml Ultrafiltration

    Patients undergoing hemodialysis with than 2000 ml ultrafiltration

    Other: Ultrafiltration

Interventions

  • OtherUltrafiltration

    Patients are selected depending on need of ultrafiltration

06

What researchers measure

Primary outcomes

  1. Proportion of fluid recruited via endothelial wall vs lymph

    Recruitment of fluid from the interstitium calculated from fluid removal and hemoglobin changes. Proportion of recruited fluid via lymph or via capillary/venulae walls based on fluid recruitment and changes in plasma albumin and immunoglobulins G and M

    Time frame: 8 hours

Secondary outcomes

  1. Weight

    Weight (before and after hemodialysis)

    Time frame: 8 hours

  2. Blood pressure

    Impact of hypovolemia related to ultrafiltration on blood pressure

    Time frame: 8 hours

  3. Bioimpedance

    Change in Bioimpedance related to hemodialysis

    Time frame: 8 hours

07

Study locations

1 site
08

References and documents

Publications

  • Zdolsek JH, Zdolsek M, Hahn RG. Recruitment of efferent lymph during infusion of 20 % albumin. Microvasc Res. 2023 Jul;148:104539. doi: 10.1016/j.mvr.2023.104539. Epub 2023 May 6. PubMed 37156370 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Results will be presented in an international medical journal

Supporting information: Clinical study report

Time frame: Approximately 6 to 12 months after completion of the study.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2024 to primary completion in Jun 2026, 24 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Dec 2025 → Jun 2026 and completion Dec 2025 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2024
First posted
May 1, 2024
StartActual
May 6, 2024
Primary completionActual
Jun 2, 2026was Dec 2025
CompletionActual
Jun 2, 2026was Dec 2025
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 13, 2026
Sites
1 site added, 1 site removed
Show site
  • Vrinnevi Hospital · Norrköping, Sweden
Show 1 removed
  • Vrinnevi Hospital · Norrköping, Sweden
Nov 13, 2026
Primary completion
Dec 31, 2025→Jun 2, 2026 (actual)
Nov 13, 2026
Study completion
Dec 31, 2025→Jun 2, 2026 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Not yet recruiting→Completed
    1 site added, 1 site removed
    Show site
    • Vrinnevi Hospital · Norrköping, Sweden
    Show 1 removed
    • Vrinnevi Hospital · Norrköping, Sweden
    Primary completion Dec 31, 2025→Jun 2, 2026 (now actual)
    Study completion Dec 31, 2025→Jun 2, 2026 (now actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06394843
Lead sponsor
Joachim Zdolsek
Collaborators
Region Östergötland
Responsible party
Joachim Zdolsek (Associate professor, Principal investigator, University Hospital, Linkoeping) — Sponsor-investigator
First posted
May 1, 2024
Start date
May 6, 2024
Primary completion
Jun 2, 2026
Completion
Jun 2, 2026
Last update
Nov 13, 2026

Study contacts

Jonathan Bodare, MD
principal investigator · Region Oestergoetland
Erik Golsäter, MD
principal investigator · Region Oestergoetland
Fredrik Sundelin, MD
principal investigator · Region Oestergoetland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion